Head-to-head evidence
Inbrija (CVT-301) vs Melevodopa/carbidopa (Sirio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Inbrija (CVT-301)
Marketed by Merz Therapeutics
NCT02240030 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 351 participants and a clinical primary endpoint based on the UPDRS Part III motor score. Although the primary score numerically favored high-dose CVT-301 over placebo, the registry does not state whether that primary comparison was statistically significant, so the result remains unclear.
Melevodopa/carbidopa (Sirio)
Developed by Chiesi Farmaceutici
NCT00491998 · Phase 1/2 · completed
The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inbrija (CVT-301)'s landscape · Melevodopa/carbidopa (Sirio)'s landscape